Insider transactions

EDGAR

Zymeworks Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
15 transactions, 256,798 shares
Sum of shares × price per share: 6,448,804.7185

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 77

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-18 Filed 2026-11-18Platshon Scott Officer: EVP, Chief Business Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)37,0370—37,037Direct (D) No
F1
  • F1 Represents shares of common stock issued upon vesting of one third of the restricted stock units (RSUs) granted on November 18, 2025.
Open filing 0001816539-26-000005 Read from the filing’s XML Dispute this row
2026-11-18 Filed 2026-11-18Platshon Scott Officer: EVP, Chief Business Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)15,29224.95
381,535.4

Derived: shares × price per share. Exact value 381535.40.

21,745Direct (D) No
F2, F3
  • F2 Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory sell to cover provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.88 to $25.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open filing 0001816539-26-000005 Read from the filing’s XML Dispute this row
2026-11-18 Filed 2026-11-18Platshon Scott Officer: EVP, Chief Business Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Unit — underlying Common Stock (37,037)
Acquired (A)37,0370—74,074Direct (D) No
F4, F5
  • F4 Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
  • F5 RSUs granted November 18, 2025; vest in three equal annual instalments beginning November 18, 2026.
Open filing 0001816539-26-000005 Read from the filing’s XML Dispute this row
2026-11-13 Filed 2026-11-16Moore Paul Andrew Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)25,0005.82
145,500

Derived: shares × price per share. Exact value 145500.00.

73,497Direct (D) No— Open filing 0001938192-26-000007 Read from the filing’s XML Dispute this row
2026-11-13 Filed 2026-11-16Moore Paul Andrew Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)7,36726.14
192,573.38

Derived: shares × price per share. Exact value 192573.38.

66,130Direct (D) No
F1
  • F1 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.07 to $26.21, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open filing 0001938192-26-000007 Read from the filing’s XML Dispute this row
2026-11-13 Filed 2026-11-16Moore Paul Andrew Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)7,37426.09
192,387.66

Derived: shares × price per share. Exact value 192387.66.

58,756Direct (D) No
F2
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.05 to $26.15, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open filing 0001938192-26-000007 Read from the filing’s XML Dispute this row
2026-11-13 Filed 2026-11-16Moore Paul Andrew Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)25,00026.04
651,000

Derived: shares × price per share. Exact value 651000.00.

33,756Direct (D) No
F3
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.95 to $26.11, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open filing 0001938192-26-000007 Read from the filing’s XML Dispute this row
2026-11-13 Filed 2026-11-16Moore Paul Andrew Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (25,000) — exercise price 5.82
Disposed (D)25,0000—175,000Direct (D) No
F4
  • F4 Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.
Open filing 0001938192-26-000007 Read from the filing’s XML Dispute this row
2026-10-09 Filed 2026-10-09Schayowitz Adam Officer: EVP, Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)37,0370—37,037Direct (D) No
F1
  • F1 Represents shares of common stock issued upon vesting of one third of the restricted stock units (RSUs) granted on October 9, 2025.
Open filing 0002127119-26-000006 Read from the filing’s XML Dispute this row
2026-10-09 Filed 2026-10-09Schayowitz Adam Officer: EVP, Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)13,83225.85
357,557.2

Derived: shares × price per share. Exact value 357557.20.

23,205Direct (D) No
F2, F3
  • F2 Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory sell to cover provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.85 to $25.88, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open filing 0002127119-26-000006 Read from the filing’s XML Dispute this row
2026-10-09 Filed 2026-10-09Schayowitz Adam Officer: EVP, Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Unit — underlying Common Stock (37,037)
Disposed (D)37,0370—74,074Direct (D) No
F4, F5
  • F4 Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
  • F5 Restricted stock units (RSUs) granted October 9, 2025; vest in three equal annual installments beginning October 9, 2026.
Open filing 0002127119-26-000006 Read from the filing’s XML Dispute this row
2026-07-06 Filed 2026-07-06Hollywood Mark Officer: EVP Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)93922.22
20,864.58

Derived: shares × price per share. Exact value 20864.58.

133,852Direct (D) No
F1, F2
  • F1 The shares were acquired under the Issuer's Employee Stock Purchase Plan (the ESPP) for the ESPP purchase period of January 1, 2026 to June 30, 2026.
  • F2 The purchase price reflects a 15% discount to the closing price of the Issuer's Common Stock on June 30, 2026 pursuant to the provisions of the ESPP.
Open filing 0002104446-26-000009 Read from the filing’s XML Dispute this row
2026-05-13 Filed 2026-05-15Schneider Paul R Officer: EVP, General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (178,000) — exercise price 24.57
Acquired (A)178,0000.00
0

Derived: shares × price per share. Exact value 0.00.

178,000Direct (D) No
F1
  • F1 Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
Open filing 0001193125-26-227140 Read from the filing’s XML Dispute this row
2026-05-13 Filed 2026-05-15Schneider Paul R Officer: EVP, General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Stock (119,000)
Acquired (A)119,0000.00
0

Derived: shares × price per share. Exact value 0.00.

119,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
  • F3 RSUs vest in four equal annual installments beginning on first anniversary of grant date.
Open filing 0001193125-26-227140 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-10Schayowitz Adam Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (70,000) — exercise price 27.35
Acquired (A)70,0000.00
0

Derived: shares × price per share. Exact value 0.00.

70,000Direct (D) No
F1
  • F1 Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
Open filing 0001193125-26-151265 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-10Schayowitz Adam Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Stock (47,000)
Acquired (A)47,0000.00
0

Derived: shares × price per share. Exact value 0.00.

47,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
  • F3 RSUs vest in four equal annual installments beginning on first anniversary of grant date.
Open filing 0001193125-26-151265 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-10Schayowitz Adam Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Performance Stock Unit — underlying Common Stock (76,000)
Acquired (A)76,0000.00
0

Derived: shares × price per share. Exact value 0.00.

76,000Direct (D) No
F4, F5
  • F4 Each performance restricted stock unit (PSU) represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return (TSR) goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 38,000 PSUs (Target Number) may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index.
  • F5 (Continued from footnote 1) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control).
Open filing 0001193125-26-151265 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-10Platshon Scott Officer: EVP, Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (70,000) — exercise price 27.35
Acquired (A)70,0000.00
0

Derived: shares × price per share. Exact value 0.00.

70,000Direct (D) No
F1
  • F1 Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
Open filing 0001193125-26-151264 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-10Platshon Scott Officer: EVP, Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Stock (47,000)
Acquired (A)47,0000.00
0

Derived: shares × price per share. Exact value 0.00.

47,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
  • F3 RSUs vest in four equal annual installments beginning on first anniversary of grant date.
Open filing 0001193125-26-151264 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-10Platshon Scott Officer: EVP, Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Performance Stock Unit — underlying Common Stock (76,000)
Acquired (A)76,0000.00
0

Derived: shares × price per share. Exact value 0.00.

76,000Direct (D) No
F4, F5
  • F4 Each performance restricted stock unit (PSU) represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return (TSR) goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 38,000 PSUs (Target Number) may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index.
  • F5 (Continued from footnote 4) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control).
Open filing 0001193125-26-151264 Read from the filing’s XML Dispute this row
2026-04-06 Filed 2026-04-07Stafford Kristin Officer: EVP, Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (178,000) — exercise price 25.84
Acquired (A)178,0000.00
0

Derived: shares × price per share. Exact value 0.00.

178,000Direct (D) No
F1
  • F1 Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
Open filing 0001193125-26-145305 Read from the filing’s XML Dispute this row
2026-04-06 Filed 2026-04-07Stafford Kristin Officer: EVP, Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Stock (119,000)
Acquired (A)119,0000.00
0

Derived: shares × price per share. Exact value 0.00.

119,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
  • F3 RSUs vest in four equal annual installments beginning on first anniversary of grant date.
Open filing 0001193125-26-145305 Read from the filing’s XML Dispute this row
2026-04-06 Filed 2026-04-07Stafford Kristin Officer: EVP, Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Stock (50,000)
Acquired (A)50,0000.00
0

Derived: shares × price per share. Exact value 0.00.

50,000Direct (D) No
F2, F4
  • F2 Each restricted stock unit (RSU) represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
  • F4 RSUs vest in three equal annual installments beginning on first anniversary of grant date.
Open filing 0001193125-26-145305 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-13Hollywood Mark Officer: EVP Chief Operating Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)17,6660.00
0

Derived: shares × price per share. Exact value 0.00.

139,033Direct (D) No
F1
  • F1 Represents shares of common stock issued upon vesting of one third of the restricted stock units (RSUs) granted on January 10, 2025.
Open filing 0001193125-26-011885 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-13Hollywood Mark Officer: EVP Chief Operating Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)6,12022.6735
138,761.82

Derived: shares × price per share. Exact value 138761.8200.

132,913Direct (D) No
F2, F3
  • F2 Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory sell to cover provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open filing 0001193125-26-011885 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-13Hollywood Mark Officer: EVP Chief Operating Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Unit — underlying Common Stock (17,666)
Disposed (D)17,6660.00
0

Derived: shares × price per share. Exact value 0.00.

35,334Direct (D) No
F4, F5
  • F4 Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
  • F5 The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date.
Open filing 0001193125-26-011885 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-13Hollywood Mark Officer: EVP Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (70,000) — exercise price 23.16
Acquired (A)70,0000.00
0

Derived: shares × price per share. Exact value 0.00.

70,000Direct (D) No
F6
  • F6 Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
Open filing 0001193125-26-011885 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-13Hollywood Mark Officer: EVP Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Stock (47,000)
Acquired (A)47,0000.00
0

Derived: shares × price per share. Exact value 0.00.

47,000Direct (D) No
F4, F7
  • F4 Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
  • F7 RSUs vest in four equal annual installments beginning on first anniversary of grant date.
Open filing 0001193125-26-011885 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-13Hollywood Mark Officer: EVP Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Performance Stock Unit — underlying Common Stock (66,000)
Acquired (A)66,0000.00
0

Derived: shares × price per share. Exact value 0.00.

66,000Direct (D) No
F8, F9
  • F8 Each performance restricted stock unit (PSU) represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return (TSR) goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 33,000 PSUs (Target Number) may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index.
  • F9 (Continued from footnote 8) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control).
Open filing 0001193125-26-011885 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-13Cherry Brian N Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (23,000) — exercise price 23.16
Acquired (A)23,0000.00
0

Derived: shares × price per share. Exact value 0.00.

23,000Direct (D) No
F1
  • F1 Stock options vest in 36 equal monthly installments starting one month after grant date of January 12, 2026.
Open filing 0001193125-26-011793 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-13Cherry Brian N Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Stock (15,400)
Acquired (A)15,4000.00
0

Derived: shares × price per share. Exact value 0.00.

15,400Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
  • F3 RSUs vest in three equal annual installments beginning on first anniversary of grant date.
Open filing 0001193125-26-011793 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Cesano Alessandra Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (11,500) — exercise price 23.16
Acquired (A)11,5000.00
0

Derived: shares × price per share. Exact value 0.00.

11,500Direct (D) No
F1
  • F1 Stock options vest on January 12, 2027.
Open filing 0001193125-26-010856 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Cesano Alessandra Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Stock (7,700)
Acquired (A)7,7000.00
0

Derived: shares × price per share. Exact value 0.00.

7,700Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
  • F3 RSUs vest on January 12, 2027.
Open filing 0001193125-26-010856 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Ciongoli Gregory Austin Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (11,500) — exercise price 23.16
Acquired (A)11,5000.00
0

Derived: shares × price per share. Exact value 0.00.

11,500Direct (D) No
F1
  • F1 Stock options vest on January 12, 2027.
Open filing 0001193125-26-010864 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Ciongoli Gregory Austin Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Stock (7,700)
Acquired (A)7,7000.00
0

Derived: shares × price per share. Exact value 0.00.

7,700Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
  • F3 RSUs vest on January 12, 2027.
Open filing 0001193125-26-010864 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Mahony Susan Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (11,500) — exercise price 23.16
Acquired (A)11,5000.00
0

Derived: shares × price per share. Exact value 0.00.

11,500Direct (D) No
F1
  • F1 Stock options vest on January 12, 2027.
Open filing 0001193125-26-010843 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Mahony Susan Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Stock (7,700)
Acquired (A)7,7000.00
0

Derived: shares × price per share. Exact value 0.00.

7,700Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
  • F3 RSUs vest on January 12, 2027.
Open filing 0001193125-26-010843 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Galbraith Kenneth Director · Officer: Chair CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)64,0000.00
0

Derived: shares × price per share. Exact value 0.00.

257,266Direct (D) No
F1
  • F1 Represents shares of common stock issued upon vesting of one third of the restricted stock units (RSUs) granted on January 10, 2025.
Open filing 0001193125-26-010790 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Galbraith Kenneth Director · Officer: Chair CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)30,42422.6735
689,818.564

Derived: shares × price per share. Exact value 689818.5640.

226,842Direct (D) No
F2, F3
  • F2 Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory sell to cover provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open filing 0001193125-26-010790 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Galbraith Kenneth Director · Officer: Chair CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Unit — underlying Common Stock (64,000)
Disposed (D)64,0000.00
0

Derived: shares × price per share. Exact value 0.00.

128,000Direct (D) No
F4, F5
  • F4 Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
  • F5 The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date.
Open filing 0001193125-26-010790 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Galbraith Kenneth Director · Officer: Chair CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (216,000) — exercise price 23.16
Acquired (A)216,0000.00
0

Derived: shares × price per share. Exact value 0.00.

216,000Direct (D) No
F6
  • F6 Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
Open filing 0001193125-26-010790 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Galbraith Kenneth Director · Officer: Chair CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Stock (144,000)
Acquired (A)144,0000.00
0

Derived: shares × price per share. Exact value 0.00.

144,000Direct (D) No
F4, F7
  • F4 Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
  • F7 RSUs vest in four equal annual installments beginning on first anniversary of grant date.
Open filing 0001193125-26-010790 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Galbraith Kenneth Director · Officer: Chair CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Performance Stock Unit — underlying Common Stock (222,000)
Acquired (A)222,0000.00
0

Derived: shares × price per share. Exact value 0.00.

222,000Direct (D) No
F8, F9
  • F8 Each performance restricted stock unit (PSU) represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return (TSR) goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 111,000 PSUs (Target Number) may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the reporting person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals,
  • F9 (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control).
Open filing 0001193125-26-010790 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Campoy Carlos Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (11,500) — exercise price 23.16
Acquired (A)11,5000.00
0

Derived: shares × price per share. Exact value 0.00.

11,500Direct (D) No
F1
  • F1 Stock options vest on January 12, 2027.
Open filing 0001193125-26-010852 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Campoy Carlos Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Stock (7,700)
Acquired (A)7,7000.00
0

Derived: shares × price per share. Exact value 0.00.

7,700Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
  • F3 RSUs vest on January 12, 2027.
Open filing 0001193125-26-010852 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Smith Jeffrey T L Officer: EVP Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)17,6660.00
0

Derived: shares × price per share. Exact value 0.00.

36,018Direct (D) No
F1
  • F1 Represents shares of common stock issued upon vesting of one third of the restricted stock units (RSUs) granted on January 10, 2025.
Open filing 0001193125-26-010865 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Smith Jeffrey T L Officer: EVP Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)9,31022.6735
211,090.285

Derived: shares × price per share. Exact value 211090.2850.

26,708Direct (D) No
F2, F3
  • F2 Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory sell to cover provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open filing 0001193125-26-010865 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Smith Jeffrey T L Officer: EVP Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Unit — underlying Common Stock (17,666)
Disposed (D)17,6660.00
0

Derived: shares × price per share. Exact value 0.00.

35,334Direct (D) No
F4, F5
  • F4 Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
  • F5 The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date.
Open filing 0001193125-26-010865 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Moore Paul Andrew Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)17,6660.00
0

Derived: shares × price per share. Exact value 0.00.

58,057Direct (D) No
F1
  • F1 Represents shares of common stock issued upon vesting of one third of the restricted stock units (RSUs) granted on January 10, 2025.
Open filing 0001193125-26-010834 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-12Moore Paul Andrew Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)9,56022.6735
216,758.66

Derived: shares × price per share. Exact value 216758.6600.

48,497Direct (D) No
F2, F3
  • F2 Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory sell to cover provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open filing 0001193125-26-010834 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,925 filings read, the latest filed 2026-11-19. Prior quarter ending 2026-06-30: 9,176 filings read.

Showing 1–50 of 215

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
EcoR1 Capital, LLC 22,970,388 SH608,485,578 dollarsUnchanged Prior quarter: 22,970,388Open filing 0000935836-26-000577 Filed 2026-11-16 Dispute this row
Rubric Capital Management LP 7,000,000 SH185,430,000 dollarsUnchanged Prior quarter: 7,000,000Open filing 0001104659-26-128244 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager4,212,745 SH111,595,615 dollarsLower by 38,285 Prior quarter: 4,251,030Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
PERCEPTIVE ADVISORS LLC 3,545,501 SH93,920,321 dollarsLower by 637,452 Prior quarter: 4,182,953Open filing 0001012975-26-001063 Filed 2026-11-16 Dispute this row
BVF INC/IL Partly reported under another manager3,464,142 SH91,765,122 dollarsLower by 185,000 Prior quarter: 3,649,142Open filing 0000921895-26-003162 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager3,236,915 SH85,745,882 dollarsHigher by 1,005,655 Prior quarter: 2,231,260Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Partly reported under another manager1,781,031 SH47,179,511 dollarsLower by 85 Prior quarter: 1,781,116Open filing 0001520354-26-000046 Filed 2026-11-13 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 1,558,998 SH41,297,857 dollarsUnchanged Prior quarter: 1,558,998Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
Assenagon Asset Management S.A. 1,508,069 SH39,948,748 dollarsLower by 995,985 Prior quarter: 2,504,054Open filing 0001546007-26-000008 Filed 2026-10-15 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager1,192,391 SH31,586,438 dollarsHigher by 278,255 Prior quarter: 914,136Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
Nextech Invest Ltd. 1,113,946 SH29,508,430 dollarsUnchanged Prior quarter: 1,113,946Open filing 0001595430-26-000015 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager1,094,008 SH28,980,272 dollarsHigher by 5,792 Prior quarter: 1,088,216Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager954,409 SH25,282,295 dollarsHigher by 483,587 Prior quarter: 470,822Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. Partly reported under another manager874,776 SH23,172,816 dollarsLower by 15,026 Prior quarter: 889,802Open filing 0000905148-26-004861 Filed 2026-11-16 Dispute this row
Prosight Management, LP 721,100 SH19,101,939 dollarsHigher by 46,666 Prior quarter: 674,434Open filing 0001420506-26-002713 Filed 2026-11-13 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager684,966 SH18,144,163 dollarsLower by 7,444 Prior quarter: 692,410Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Fisher Asset Management, LLC Partly reported under another manager608,612 SH16,122,131 dollarsHigher by 537,837 Prior quarter: 70,775Open filing 0000850529-26-000009 Filed 2026-11-06 Dispute this row
Vestal Point Capital, LP 600,000 SH15,894,000 dollarsNot in the prior quarter’s filings read Open filing 0001974915-26-000008 Filed 2026-11-16 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager530,448 SH14,051,568 dollarsLower by 464,507 Prior quarter: 994,955Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
Redmile Group, LLC 491,654 SH13,023,914 dollarsUnchanged Prior quarter: 491,654Open filing 0000905148-26-004923 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 469,847 SH12,446,247 dollarsLower by 40,185 Prior quarter: 510,032Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
MILLENNIUM MANAGEMENT LLC 400,074 SH10,597,960 dollarsNot in the prior quarter’s filings read Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
DEUTSCHE BANK AG\ Partly reported under another manager390,842 SH10,353,404 dollarsLower by 6,348 Prior quarter: 397,190Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row
Man Group plc Partly reported under another manager342,191 SH9,064,639 dollarsHigher by 131,412 Prior quarter: 210,779Open filing 0001637460-26-000004 Filed 2026-11-16 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager314,293 SH8,325,622 dollarsLower by 6,780 Prior quarter: 321,073Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
Hillsdale Investment Management Inc. 276,372 SH7,321,095 dollarsLower by 106,550 Prior quarter: 382,922Open filing 0001193125-26-457091 Filed 2026-11-12 Dispute this row
SILVERCREST ASSET MANAGEMENT GROUP LLC 276,038 SH7,312,247 dollarsHigher by 52,272 Prior quarter: 223,766Open filing 0001193125-26-462346 Filed 2026-11-16 Dispute this row
FEDERATED HERMES, INC. Partly reported under another manager246,979 SH6,542,474 dollarsHigher by 58,984 Prior quarter: 187,995Open filing 0001623632-26-001675 Filed 2026-11-12 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager233,441 SH6,183,852 dollarsHigher by 88,634 Prior quarter: 144,807Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
Jump Financial, LLC Partly reported under another manager230,236 SH6,098,952 dollarsHigher by 204,628 Prior quarter: 25,608Open filing 0000905148-26-004786 Filed 2026-11-13 Dispute this row
FMR LLC Partly reported under another manager230,164 SH6,097,050 dollarsLower by 472,404 Prior quarter: 702,568Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
WELLS FARGO COMPANY/MN Partly reported under another manager228,279 SH6,047,102 dollarsHigher by 11,080 Prior quarter: 217,199Open filing 0000072971-26-000342 Filed 2026-11-16 Dispute this row
PICTON MAHONEY ASSET MANAGEMENT 225,489 SH5,973,206 dollarsLower by 45,854 Prior quarter: 271,343Open filing 0001539041-26-000039 Filed 2026-11-09 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager222,443 SH5,892,516 dollarsHigher by 3,372 Prior quarter: 219,071Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
Granahan Investment Management, LLC 219,649 SH5,818,502 dollarsLower by 116,508 Prior quarter: 336,157Open filing 0001398344-26-020113 Filed 2026-11-16 Dispute this row
Pictet Asset Management Holding SA 188,468 SH5,120,814 dollarsLower by 119,719 Prior quarter: 308,187Open filing 0001993888-26-000007 Filed 2026-11-03 Dispute this row
KENNEDY CAPITAL MANAGEMENT LLC 177,151 SH4,692,730 dollarsHigher by 31,765 Prior quarter: 145,386Open filing 0000884589-26-000015 Filed 2026-11-13 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager169,778 SH5,252,931 dollarsHigher by 93,250 Prior quarter: 76,528Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
Invesco Ltd. Partly reported under another manager169,585 SH4,492,307 dollarsHigher by 57,373 Prior quarter: 112,212Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
HRT FINANCIAL LP 167,514 SH4,437 dollarsNot in the prior quarter’s filings read Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row
Campbell CO Investment Adviser LLC 159,514 SH4,225,526 dollarsHigher by 98,640 Prior quarter: 60,874Open filing 0001140361-26-043564 Filed 2026-11-13 Dispute this row
RAYMOND JAMES FINANCIAL INC Partly reported under another manager151,259 SH4,006,850 dollarsLower by 15,157 Prior quarter: 166,416Open filing 0000720005-26-000081 Filed 2026-11-12 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager134,873 SH3,668,545 dollarsHigher by 28,475 Prior quarter: 106,398Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
TWO SIGMA INVESTMENTS, LP 133,873 SH3,546,296 dollarsHigher by 61,999 Prior quarter: 71,874Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
AQR CAPITAL MANAGEMENT LLC Partly reported under another manager130,337 SH3,452,628 dollarsHigher by 19,055 Prior quarter: 111,282Open filing 0001167557-26-000324 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager129,171 SH3,421,740 dollarsHigher by 14,076 Prior quarter: 115,095Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager128,828 SH3,412,645 dollarsLower by 2,278 Prior quarter: 131,106Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
MACKENZIE FINANCIAL CORP 121,617 SH3,221,634 dollarsHigher by 33,872 Prior quarter: 87,745Open filing 0001062993-26-005652 Filed 2026-11-02 Dispute this row
LMR Partners LLP Partly reported under another manager120,000 SH3,178,800 dollarsHigher by 37,500 Prior quarter: 82,500Open filing 0001578621-26-000193 Filed 2026-11-16 Dispute this row
Nuveen, LLC Partly reported under another manager119,032 SH3,153,158 dollarsLower by 357 Prior quarter: 119,389Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Capricorn Fund Managers Ltd 486,529 SH
  • SummitTX Capital, L.P. 210,802 SH
  • Sixth Street Partners Management Company, L.P. 152,416 SH
  • DIADEMA PARTNERS LP 142,132 SH
  • PANAGORA ASSET MANAGEMENT INC 118,603 SH
  • WELLINGTON MANAGEMENT GROUP LLP 110,014 SH
  • PRINCIPAL FINANCIAL GROUP INC 84,990 SH
  • TUDOR INVESTMENT CORP ET AL 36,471 SH
  • Persistent Asset Partners Ltd 35,935 SH
  • STRS OHIO 26,500 SH
  • Brevan Howard Capital Management LP 25,956 SH
  • Jupiter Topco LLC 18,200 SH
  • JANE STREET GROUP, LLC 17,437 SH
  • HSBC HOLDINGS PLC 15,588 SH
  • INTECH INVESTMENT MANAGEMENT LLC 11,935 SH
  • PSP Research LLC 10,000 SH
  • Allspring Global Investments Holdings, LLC 8,762 SH
  • INCEPTIONR LLC 8,313 SH
  • Magnetar Financial LLC 8,292 SH
  • SG Americas Securities, LLC 6,321 SH
  • MERCER GLOBAL ADVISORS INC /ADV 3,893 SH
  • DekaBank Deutsche Girozentrale 3,843 SH
  • Asset Management One Co., Ltd. 1,659 SH
  • Eurizon Capital SGR S.p.A. 1,321 SH
  • Caitong International Asset Management Co., Ltd 1,309 SH
  • Freestone Grove Partners LP 648 SH
  • Inspire Investing, LLC 332 SH
  • Integrated Wealth Concepts LLC 295 SH
  • Quarry LP 210 SH
  • Kilter Group LLC 66 SH
  • INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC 25 SH
  • Clearstead Advisors, LLC 6 SH
  • Silver Grove Financial Group, Inc. 4 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Perceptive Advisors LLC Common Stock, $0.00001 par value per share5.43,974,57904/08/2026 Filed 2026-04-15SCHEDULE 13GOpen filing 0001193125-26-157043 Dispute this row
Joseph Edelman Common Stock, $0.00001 par value per share5.43,974,57904/08/2026 Filed 2026-04-15SCHEDULE 13GOpen filing 0001193125-26-157043 Dispute this row
Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.00001 par value per share5.43,974,57904/08/2026 Filed 2026-04-15SCHEDULE 13GOpen filing 0001193125-26-157043 Dispute this row
Rubric Capital Management LP Common Stock, $0.00001 par value per share9.497,000,000.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-062529 Dispute this row
David Rosen Common Stock, $0.00001 par value per share9.497,000,000.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-062529 Dispute this row
Rubric Capital Management LP Common Stock, $0.00001 par value per share7.685,750,000.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-015252 Dispute this row
David Rosen Common Stock, $0.00001 par value per share7.685,750,000.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-015252 Dispute this row
Morgan Stanley Common Stock3.42,519,24312/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 3Open filing 0000895421-26-000053 Dispute this row
EcoR1 Capital, LLC Common Stock30.722,970,388.0011/16/2025 Filed 2025-11-19SCHEDULE 13D/AAmendment 7Open filing 0000935836-25-000711 Dispute this row
Oleg Nodelman Common Stock30.722,970,388.0011/16/2025 Filed 2025-11-19SCHEDULE 13D/AAmendment 7Open filing 0000935836-25-000711 Dispute this row
EcoR1 Capital Fund Qualified, L.P. Common Stock28.821,582,563.0011/16/2025 Filed 2025-11-19SCHEDULE 13D/AAmendment 7Open filing 0000935836-25-000711 Dispute this row
Redmile Group, LLC Common Stock, par value $0.00001 per share4.93,705,750.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 6Open filing 0001104659-25-112552 Dispute this row
Jeremy C. Green Common Stock, par value $0.00001 per share4.93,705,750.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 6Open filing 0001104659-25-112552 Dispute this row
BIOTECHNOLOGY VALUE FUND L P Common Stock, $0.00001 par value per share2.72,045,162.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-25-003117 Dispute this row
BVF I GP LLC Common Stock, $0.00001 par value per share2.72,045,162.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-25-003117 Dispute this row
BIOTECHNOLOGY VALUE FUND II LP Common Stock, $0.00001 par value per share2.11,601,489.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-25-003117 Dispute this row
BVF II GP LLC Common Stock, $0.00001 par value per share2.11,601,489.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-25-003117 Dispute this row
Biotechnology Value Trading Fund OS LP Common Stock, $0.00001 par value per share0.3212,898.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-25-003117 Dispute this row
BVF Partners OS Ltd. Common Stock, $0.00001 par value per share0.3212,898.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-25-003117 Dispute this row
BVF GP HOLDINGS LLC Common Stock, $0.00001 par value per share4.93,646,651.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-25-003117 Dispute this row
BVF PARTNERS L P/IL Common Stock, $0.00001 par value per share5.23,938,641.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-25-003117 Dispute this row
BVF INC/IL Common Stock, $0.00001 par value per share5.23,938,641.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-25-003117 Dispute this row
LAMPERT MARK N Common Stock, $0.00001 par value per share5.23,938,641.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-25-003117 Dispute this row
Redmile Group, LLC Common Stock, par value $0.00001 per share5.64,150,627.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 5Open filing 0001104659-25-078645 Dispute this row
Jeremy C. Green Common Stock, par value $0.00001 per share5.64,150,627.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 5Open filing 0001104659-25-078645 Dispute this row
Redmile Biopharma Investments III, L.P. Common Stock, par value $0.00001 per share4.63,470,727.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 5Open filing 0001104659-25-078645 Dispute this row
BlackRock, Inc. Common Stock4.83,559,82806/30/2025 Filed 2025-07-16SCHEDULE 13G/AAmendment 1Open filing 0002052113-25-002527 Dispute this row
EcoR1 Capital, LLC Common Stock30.722,970,388.0006/26/2025 Filed 2025-06-27SCHEDULE 13DOpen filing 0000935836-25-000439 Dispute this row
Oleg Nodelman Common Stock30.722,970,388.0006/26/2025 Filed 2025-06-27SCHEDULE 13DOpen filing 0000935836-25-000439 Dispute this row
EcoR1 Capital Fund Qualified, L.P. Common Stock28.821,582,563.0006/26/2025 Filed 2025-06-27SCHEDULE 13DOpen filing 0000935836-25-000439 Dispute this row
EcoR1 Capital, LLC Common Stock21.314,692,281.0012/19/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 1Open filing 0000935836-24-000776 Dispute this row
Oleg Nodelman Common Stock21.314,692,281.0012/19/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 1Open filing 0000935836-24-000776 Dispute this row
EcoR1 Capital Fund Qualified, L.P. Common Stock20.113,839,128.0012/19/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 1Open filing 0000935836-24-000776 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,671,519 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201588,606
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,123

Filings made before the SEC required XML are listed, not extracted.

Back to Zymeworks Inc.